We are live on !
Find out more
FCPM III Services Portfolio holdings
AUM
$750M
Turnover
9.09%
1-Year Est. Return
127.27%
This Fund
S&P 500
This Quarter Est. Return
+17.01%
1 Year Est. Return
+127.27%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$750M
AUM Growth
+$28.2M
(+3.9%)
Cap. Flow
-$9.15M
Cap. Flow % of AUM
Cap. Flow %
-1.22%
Top 10 Holdings %
Top 10 Hldgs %
99.89%
Holding
11
New
1
Increased
–
Reduced
2
Closed
–
Avg Time Held
1.5
years
Top 10 Avg Time Held
1.4
years
Top 20 Avg Time Held
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aura Biosciences
AURA
|
+$29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NewAmsterdam Pharma
NAMS
|
+$23.3M |
| 2 |
Dyne Therapeutics
DYN
|
+$14.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.89% |
| 2 | Miscellaneous | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
NewAmsterdam Pharma
NAMS
$2.44B
| $288M | 38.34% |
8,490,353
-708,547
| -8% | -$23.3M |
2023 Q4
10 quarters
|
|
2
MapLight Therapeutics
MPLT
$441M
| $116M | 15.41% |
3,226,400
| – | – |
2025 Q4
2 quarters
|
|
|
3
Dyne Therapeutics
DYN
$2.82B
| $85.5M | 11.39% |
3,848,256
-796,130
| -17% | -$14.8M |
2023 Q4
10 quarters
|
|
4
Vor Biopharma
VOR
$1.07B
| $75.8M | 10.1% |
4,117,354
| – | – |
2025 Q3
3 quarters
|
|
|
DMRA
5
Damora Therapeutics
DMRA
$1.2B
| $63.5M | 8.46% |
2,441,000
| – | – |
2026 Q1
1 quarter
|
|
6
Replimune Group
REPL
$1.03B
| $31.1M | 4.14% |
2,808,368
| – | – |
2023 Q4
10 quarters
|
|
7
Crescent Biopharma
CBIO
$463M
| $30.2M | 4.02% |
1,677,852
| – | – |
2025 Q4
2 quarters
|
|
|
8
Aura Biosciences
AURA
$653M
| $28.8M | 3.84% |
+4,053,775
| New | +$29M |
2026 Q2
0 quarters
|
|
9
enGene Therapeutics
ENGN
$110M
| $16.7M | 2.22% |
9,632,561
| – | – |
2023 Q4
10 quarters
|
|
10
Bicycle Therapeutics
BCYC
$252M
| $14.7M | 1.96% |
3,468,430
| – | – |
2024 Q2
8 quarters
|
|
|
11
enGene Therapeutics Warrants
ENGNW
$1.67M
| $834K | 0.11% |
2,878,148
| – | – |
2023 Q4
10 quarters
|
|
Similar funds
FCPM III Services's Q2 2026 Portfolio in Review
As of Q2 2026, FCPM III Services held 11 positions worth $750M, up 3.9% from $722M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
FCPM III Services's Q2 2026 filing shows 1 new and 2 reduced positions. Its largest new stake was Aura Biosciences: 4,053,775 shares worth $28.8M. The largest sale was NewAmsterdam Pharma, an estimated $23.3M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.
- FCPM III Services's largest Q2 2026 buy was Aura Biosciences: 4,053,775 shares worth $28.8M.
- FCPM III Services's biggest Q2 2026 reduction was NewAmsterdam Pharma, cutting an estimated $23.3M.
- FCPM III Services's ten largest holdings make up 100% of its $750M portfolio in Q2 2026.
- FCPM III Services opened 1 new position and closed 0 in Q2 2026.
- FCPM III Services's portfolio value rose 3.9% quarter-over-quarter to $750M.
Based on FCPM III Services's 13F filing for Q2 2026, filed 14 Aug 2026.